文献速递前列腺癌

前列腺癌筛查实践与流行病学的近期变化

Recent Changes in Prostate Cancer Screening Practices and Epidemiology.
PubMed 文献 · J Urol · 2017-05-25

本文综述2012年至2016年底关于美国预防服务工作组(USPSTF)推荐对前列腺特异性抗原(PSA)筛查及前列腺癌发病率影响的26项原创研究。结果显示PSA检测和前列腺活检减少,局限性前列腺癌(包括低、中、高危)发病率下降;分期数据尚不成熟,但已有向更高疾病负荷转变的早期迹象。作者担忧这可能逆转既往几十年前列腺癌特异性死亡率的改善。

要点

  • USPSTF于2008年推荐反对筛查75岁以上男性,2012年反对对所有男性常规筛查。
  • 2012年至2016年底的文献显示PSA检测和前列腺活检减少,局限性前列腺癌发病率下降。
  • 分期分布数据尚不成熟,但已有向更高疾病负荷转变的早期迹象。

核心结论

  • 这些发现引发了对既往几十年观察到的前列腺癌特异性死亡率改善可能逆转的担忧。
  • 替代筛查策略应:1)通过共享决策纳入患者偏好;2)保留筛查相关的生存获益;3)提高筛查特异性以减少不必要的活检和低危疾病检出;4)对检出的低危癌症促进主动监测的应用。

研究设计与样本

  • 英文文献检索,检索词包括「prostate specific antigen」「screening」和「United States Preventive Services Task Force」的不同组合。
  • 截至2016年12月1日,共纳入26项关于USPSTF推荐对美国PSA筛查或前列腺癌发病率影响的原创研究。

主要发现

  • 2012年至2016年底的文献综述表明,PSA检测和前列腺活检减少。
  • 因此,局限性前列腺癌发病率下降,包括低、中和高危疾病。
  • 关于就诊时分期数据尚不成熟,但已有一些向就诊时更高疾病负荷转变的早期迹象。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate specific antigen based screening for prostate cancer has had a significant impact on the epidemiology of the disease. Its use has been associated with a significant decrease in prostate cancer mortality but has also resulted in the over diagnosis and overtreatment of indolent prostate cancer, exposing many men to the harms of treatment without benefit. The USPSTF (U.S. Preventive Services Task Force) in 2008 issued a recommendation against screening men older than 75 years, and in 2012 against routine screening for all men, indicating that in its interpretation the harms of screening outweigh the benefits. We review changes in the use of prostate specific antigen testing, performance of prostate biopsy, incidence of prostate cancer and stage of disease at presentation since 2012. MATERIALS AND METHODS: An English language literature search was performed for terms that included "prostate specific antigen," "screening" and "United States Preventive Services Task Force" in various combinations. A total of 26 original studies had been published on the effects of the USPSTF recommendations on prostate specific antigen based screening or prostate cancer incidence in the United States as of December 1, 2016. RESULTS: Review of the literature from 2012 through the end of 2016 indicates that there has been a decrease in prostate specific antigen testing and prostate biopsy. As a result, there has been a decline in the incidence of localized prostate cancer, including low, intermediate and high risk disease. The data regarding stage at presentation have yet to mature but there are some early signs of a shift toward higher burden of disease at presentation. CONCLUSIONS: These findings raise concern about a reversal of the observed improvement in prostate cancer specific mortality during preceding decades. Alternative screening strategies would 1) incorporate patient preferences by allowing shared decision-making, 2) preserve the survival benefits associated with screening, 3) improve the specificity of screening to reduce unnecessary biopsies and detection of low risk disease, and 4) promote the use of active surveillance for low risk cancers if they are detected.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lee DJ, Mallin K, Graves AJ, et al. Recent Changes in Prostate Cancer Screening Practices and Epidemiology. J Urol. 2017. PMID: 28552708. doi:10.1016/j.juro.2017.05.074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。